Innovation needed in weight-loss medications

Shortages of diabetes medication, Ozempic (semaglutide), fueled by off-label prescribing of it as a weight-loss treatment, highlight the need for new drugs to tackle obesity.   With supplier, Novo Nordisk reporting that supplies of Ozempic will not be available in Australia until April, patients with type 2 diabetes who use the medication to help manage

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacist soon to be paroled after arson
Next Indigenous pharmacists join APC leadership